Sinfonia Biotherapeutics
Huddinge
About Sinfonia Biotherapeutics
Sinfonia Biotherapeutics is pioneering the development of novel, bioreactor-delivered drug treatments for familial & genetically-defined orphan neurodegenerative disorders within frontotemporal lobar dementia (FTD), Alzheimer’s and Parkinson’s disorders. Just as cancer is composed of many different subtypes, they know dementia is as well. Thus, to succeed where others have failed in developing dementia treatments, they are developing breakthrough biologic therapies that target familial dementia subtypes with underlying disease mechanisms that are known.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $80.9K
- Last round: Grant (Dec 2018)
- Website: sinfoniabiotherapeutics.com
Industries & Categories
Biotechnology, Health Care
Canonical: https://fsome.com/organization/sinfonia-biotherapeutics-198623 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.